Transcode Therapeutics (RNAZ) Operating Leases (2023)

Transcode Therapeutics' (RNAZ) quarterly Operating Leases came in at $38291.0 in Q4 2023, down 79.82% on a QoQ basis from $189766.0 in Q3 2023.

Transcode Therapeutics (RNAZ) Operating Leases (2023) Analysis & Trends

Transcode Therapeutics (RNAZ) has 1 years of Operating Leases data on file, last reported at $38291.0 in Q4 2023.

Quarterly Operating Leases changed N/A year-over-year to $38291.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $38291.0 (changed N/A YoY) and the FY2023 annual result came in at $38291.0, changed N/A from the prior year.
Operating Leases eased to $38291.0 in Q4 2023, from $189766.0 in the prior quarter.
In the past five years, Operating Leases ranged from a high of $377813.0 in Q1 2023 to a low of $38291.0 in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	Transcode Therapeutics	2.84 Mn	2.84 Mn	-

Download Data